Table 9.

Summary of findings for PICO 14. Assessment of actovegin for post-stroke dementia.

Population: Recent ischaemic stroke Intervention: Actovegin daily intravenous then oral Comparator: placebo
Outcome	No of participants	Difference in mean change from baseline at 6 months	Quality of evidence (GRADE)
Cognition (ADAS-Cog)	One trial, n = 196 (actogevin) vs 202 (placebo)	Mean change from baseline: −2.3 (−3.9, −0.7); p = 0.005	Very low a
Adverse events	One trial, n = 250 (actogevin) vs 253 (placebo)	% Discontinuing due to AE actovegin: 8.4%; placebo: 6.6%	Very low b
BPSD	No data
Caregiver strain	No data

^aDowngraded due to imprecision; publication bias and inconsistency.

^bDowngraded due to serious imprecision; publication bias and inconsistency.